Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.17
+0.05000.62%
Post-market: 8.190.0200+0.24%16:42 EDT
Volume:6.14M
Turnover:49.58M
Market Cap:2.09B
PE:-5.43
High:8.20
Open:8.12
Low:7.92
Close:8.12
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.93
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.60
PE(LYR):6.75

Loading ...

J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)

TIPRANKS
·
Jul 13

Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

Simply Wall St.
·
Jul 09

Biocryst Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 07

Eupraxia Pharma Adds Robert Bazemore, Amy Pott, Helen Thackray to Board

Reuters
·
Jul 07

Kioxia Ships Next-gen Memory Samples as AI Boom Fuels Dramatic Comeback

Reuters
·
Jul 03

Biocryst Grants New Hires Stock Options for 33,950 Shares at $9.65 Each

Reuters
·
Jul 02

Biocryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Biocryst Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jun 30

BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

MT Newswires Live
·
Jun 29

Biocryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Reaffirms Full Year 2026 Orladeyo and Total Company Revenue Guidance

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Shifts Strategic Focus to External Innovation for Rare Disease Pipeline

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - to Make Orladeyo Oral Pellets Available in Early August 2026

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - to Close Birmingham Discovery Center and End Internal Discovery Programs by End 2026

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Completes Enrollment in Phase 3 Alpha-orbit Study for Navenibart

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Improves 2026 Non-gaap Operating Expense Guidance to $420-$440 Mln

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals Inc Fy2026 REV View $667.5 Mln

THOMSON REUTERS
·
Jun 29

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15